Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE: Atezolizumab and Bevacizumab in HCC and NSCLC with Liver Metastases
NCT04563338Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by University Health Network. Primary endpoint: Progression-Free Survival at 4 years. Started Jun 2021; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04563338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563338.